Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.48 |
| ▸ | KDM1A | O60341 | 10/20 | 0.47 |
| ▸ | MAOB | P27338 | 9/20 | 0.47 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 7/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30450726 | 1.00 | SLC6A2 (0.56) | SLC6A2SLC6A3SLC6A4KDM1AMAOB | |
| Hydrochloric Acid SCHEMBL6926090 | 0.97 | SLC6A2 (0.54) | SLC6A2SLC6A3SLC6A4KDM1AMAOB | |
| Hydrochloric Acid SCHEMBL6926088 | 0.97 | SLC6A2 (0.54) | SLC6A2SLC6A3SLC6A4KDM1AMAOB | |
| Hydrochloric Acid SCHEMBL6929594 | 0.97 | SLC6A2 (0.54) | SLC6A2SLC6A3SLC6A4KDM1AMAOB | |
| Hydrochloric Acid SCHEMBL6931517 | 0.97 | SLC6A2 (0.54) | SLC6A2SLC6A3SLC6A4KDM1AMAOB | |
| Hydrochloric Acid SCHEMBL6931523 | 0.97 | SLC6A2 (0.54) | SLC6A2SLC6A3SLC6A4KDM1AMAOB | |
| SCHEMBL3077728 | 0.84 | SLC6A2 (0.48) | SLC6A2SLC6A3SLC6A4KDM1AMAOB | |
| SCHEMBL5114376 | 0.84 | SLC6A2 (0.48) | SLC6A2SLC6A3SLC6A4KDM1AMAOB | |
| SCHEMBL3077730 | 0.84 | SLC6A2 (0.48) | SLC6A2SLC6A3SLC6A4KDM1AMAOB | |
| SCHEMBL783666 | 0.84 | SLC6A2 (0.48) | SLC6A2SLC6A3SLC6A4KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0865276-A4 | POLYAMINE DERIVATIVES OF 1-AMINOINDAN | GILAD GAD (IL) | 2003-07-30 | — | — | EP | claimed |
| EP-0865276-A1 | POLYAMINE DERIVATIVES OF 1-AMINOINDAN | Gilad, Gad (IL) | 1998-09-23 | — | — | EP | claimed |
| US-5646188-A | FOR TREATING NEUROTRAUMA | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1997-07-08 | — | — | US | claimed |
| WO-1997002027-A1 | POLYAMINE DERIVATIVES OF 1-AMINOINDAN | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1997-01-23 | — | — | WO | claimed |
| EP-3495349-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2023-06-28 | — | — | EP | disclosed |
| CN-109195593-A | For treating the combination of the LSD1 inhibitor of solid tumor | 奥莱松基因组股份有限公司 | 2019-01-11 | — | — | CN | disclosed |
| CN-105324359-B | Ligand compound, catalyst system for olefin oligomerization, and method for olefin oligomerization using same | 株式会社LG化学 | 2018-01-16 | — | — | CN | disclosed |
| CN-107074824-A | Phthalazine derivatives of formula (I) as PCAF and GCN5 inhibitors for the treatment of cancer | 基因泰克公司 | 2017-08-18 | — | — | CN | disclosed |
| US-9637508-B2 | Ligand compound, catalyst system for olefin oligomerization, and method for olefin oligomerization using the same | LG CHEM, LTD. (KR) | 2017-05-02 | — | — | US | disclosed |
| US-20160122371-A1 | LIGAND COMPOUND, CATALYST SYSTEM FOR OLEFIN OLIGOMERAZATION, AND METHOD FOR OLEFIN OLIGOMERIZATION USING THE SAME | LG CHEM, LTD. (KR) | 2016-05-05 | — | — | US | disclosed |
| EP-2987783-A1 | LIGAND COMPOUND, CATALYST SYSTEM FOR OLEFIN OLIGOMERIZATION, AND OLEFIN OLIGOMERIZATION METHOD USING SAME | LG Chem, Ltd. (KR) | 2016-02-24 | — | — | EP | disclosed |
| CN-105324359-A | Ligand compound, catalyst system for olefin oligomerization, and method for olefin oligomerization using same | LG CHEMICAL LTD | 2016-02-10 | — | — | CN | disclosed |
| US-20080194535-A1 | DIAMINOPROPANE DERIVED MACROCYCLES AS INHIBITORS OF BETA AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2008-08-14 | — | — | US | disclosed |
| EP-0865276-A4 | POLYAMINE DERIVATIVES OF 1-AMINOINDAN | GILAD GAD (IL) | 2003-07-30 | — | — | EP | disclosed |
| EP-0865276-A1 | POLYAMINE DERIVATIVES OF 1-AMINOINDAN | Gilad, Gad (IL) | 1998-09-23 | — | — | EP | disclosed |
| US-5646188-A | FOR TREATING NEUROTRAUMA | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1997-07-08 | — | — | US | disclosed |
| WO-1997002027-A1 | POLYAMINE DERIVATIVES OF 1-AMINOINDAN | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1997-01-23 | — | — | WO | disclosed |
| US-4414220-A | HUPOGLYCEMIC, ANTIDIABETIC | PFIZER INC. (US) | 1983-11-08 | — | — | US | disclosed |
| US-4333932-A | DIHYDROISOINDOLES, HYPOGLYCEMIC, ANTIDIABETIC | PFIZER INC. (US) | 1982-06-08 | — | — | US | disclosed |
| US-4220650-A | HYPOGLYCEMIC | PFIZER INC. (US) | 1980-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194535-A1 | DIAMINOPROPANE DERIVED MACROCYCLES AS INHIBITORS OF BETA AMYLOID PRODUCTION | APP, BACE1, BACE2 | SLC6A2 2683/4885SLC6A3 2132/4885SLC6A4 3791/4885 |
| US-20160122371-A1 | LIGAND COMPOUND, CATALYST SYSTEM FOR OLEFIN OLIGOMERAZATION, AND METHOD FOR OLEFIN OLIGOMERIZATION USING THE SAME | OXER1, OSTC, OCIAD1 | SLC6A2 4681/4885SLC6A3 4479/4885SLC6A4 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.